{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088581","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.833752+00:00","generated_at":"2026-05-31T14:29:24.036721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biomea Fusion Q2 net loss $37.3M; FDA clinical hold on diabetes trials; topline readouts on track for Q4","bullets":["Net loss $37.3M in Q2 vs $24.9M YoY; cash $113.7M, down from $177.2M end of 2023.","FDA imposed full clinical hold on BMF-219 diabetes trials due to hepatotoxicity concerns.","Topline data from Phase 2b (type 2, ~195 pts) and Phase 2a (type 1, ~20 pts) still expected Q4 2024.","Third obesity program (oral GLP-1R agonist) to be announced Q3 2024.","Two COVALENT-101 cohorts (CLL, DLBCL) discontinued due to insufficient enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088581","json":"https://secwatch.observer/filing/0000950170-24-088581.json","markdown":"https://secwatch.observer/filing/0000950170-24-088581.md","text":"https://secwatch.observer/filing/0000950170-24-088581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024088581/0000950170-24-088581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024088581/bmea-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:29:24.036721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}